Match tier
Listed
Presence
Current · Arkansas
Last published
2022
Sources
OpenAlex · ORCID
Refreshed
2026-08-18
J
Jaideep B. Bharate
Senior Research Investigator
Also affiliated: University of Jammu (2015); Indian Institute of Integrative Medicine (2012–2015); Institute of Medicinal Plant Development (2014–2015); Council of Scientific and Industrial Research (2012–2015); Umeå University (2021); Academy of Scientific and Innovative Research (2013–2015)
Faculty Researcher
16 h-index
35 pubs
770 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jaideep B. Bharate's research focuses on the discovery and optimization of novel therapeutic agents, particularly in the area of oncology. His work involves structure-based drug design and synthesis, with recent publications detailing the development of inhibitors for FLT3 and RET kinases, which are implicated in acute myeloid leukemia and certain cancers, respectively. These efforts often utilize pyrimidine and imidazo[1,2-a]pyridine derivatives as core structures. Bharate also investigates synthetic methodologies, including tandem ring opening/intramolecular cycloaddition reactions for constructing novel heterocyclic compounds. His research network includes collaborators from the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications. Bharate's scholarship is reflected in his h-index of 16, with 35 total publications and 756 citations.
Metrics
- h-index: 16
- Publications: 35
- Citations: 770
Selected Publications
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021)
-
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT (2018)
Collaboration Network
Top Collaborators
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
2 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Naga Rajiv Lakkaniga
Scripps Research Institute (US)
2 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Xiuqi Wang
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Anupreet Kharbanda
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Brendan Frett
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Hongyu Li
University of Arkansas for Medical Sciences (US)
2 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Nicholas McConnell
University of California, San Francisco (US)
1 shared publication
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
Neil P. Shah
University of California, San Francisco (US)
1 shared publication
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
Marialuisa Moccia
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
David C. Briggs
1 shared publication
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Phillip P. Knowles
1 shared publication
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Wei Yan
University of Arkansas for Medical Sciences (US)
1 shared publication
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Phuc Tran
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Massimo Santoro
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Similar Researchers
Based on overlapping research topics
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Discovery
Xiuqi Wang
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Acute Myeloid Leukemia Research
Baha’a Jabali
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Cancer-related molecular mechanisms research
Ifedi Orizu
University of Arkansas at Fayetteville
Computational Drug Discovery Methods
Synthesis and biological activity
Protein Structure and Dynamics
Ahmed D. Iqbal
Arkansas State University
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Synthesis and biological activity
Alicja Urbaniak
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research